RxDoctor Payments Data

Chris Godfrey, MD

Internal Medicine · Elizabethtown, KYNPI 1679564439

Payments from drug & device makers

$2,809in general payments, 2019–2025

Across 174 payments — averaging $16.15 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$426
  • Otsuka America Pharmaceutical, Inc.$299
  • Novo Nordisk$265
  • GSK$184
  • AstraZeneca$177
  • Amgen$148
  • plus $1K from 34 others

What the payments were for

  • Food & beverage$2,798100%
  • Education$120%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$2,809 in reported general payments places this provider in the 80th percentile of 1,284 internal medicine providers in Kentucky.

See all internal medicine providers in Kentucky

Medicare billing

Part B allowed, 2024
$447,636
Medicare patients
973
Services billed
5,226

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban1,076$562,414
TrulicityDulaglutide189$207,181
OzempicSemaglutide130$134,157
JanuviaSitagliptin Phosphate173$128,269
JardianceEmpagliflozin202$115,580
MounjaroTirzepatide100$104,354
Trelegy ElliptaFluticasone/Umeclidin/Vilanter130$98,231
XifaxanRifaximin31$50,405
XareltoRivaroxaban102$49,539
FarxigaDapagliflozin Propanediol29$30,684
VraylarCariprazine Hcl17$23,081
LinzessLinaclotide27$22,848
Breztri AerosphereBudesonide/Glycopyr/Formoterol26$22,338
JanumetSitagliptin Phos/Metformin Hcl23$22,132
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog86$21,699

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$56$562,4141,076 claims
Lilly USA, LLCTrulicity, Mounjaro$119$311,534289 claims
Novo NordiskOzempic, Levemir, Rybelsus$265$157,115237 claims
Boehringer IngelheimJardiance, Spiriva Respimat, Tradjenta$31$132,222247 claims
GSKTrelegy Ellipta, Breo Ellipta$184$110,513159 claims
AbbVieVraylar, Linzess, Qulipta$426$60,34472 claims
AstraZenecaFarxiga, Breztri Aerosphere$177$53,02255 claims
Johnson & JohnsonXarelto$122$49,539102 claims
Amneal Pharmaceuticals LLCLevothyroxine Sodium, Rytary$20$30,3781,555 claims
Astellas Pharma US IncMyrbetriq$42$20,39268 claims
Otsuka America Pharmaceutical, Inc.Rexulti$299$18,42424 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 1,284 internal medicine providers in Kentucky.

Other internal medicine in Elizabethtown

See the full list for Kentucky

Where these figures come from

Is this you, or does something look wrong? →